Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis
- Sandra Kallin, Anders Svenningsson, Ola Olén, Charlotte Hedin, Jan Lycke, and Peter Alping
- JAMA Neurology - October 2026
Abstract
Importance: Anti-CD20 biologics are widely used as disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), but recent reports have raised concerns about an increased risk of inflammatory bowel disease (IBD) during treatment. This study aimed to assess treatment-associated IBD risk in persons with RRMS.
Objective: To compare the risk of new-onset IBD across different therapies for RRMS and relative to the general population.
Design: Population-based cohort study.
Participants: Through the Swedish MS register, we identified initiations of rituximab (6,481), natalizumab (2,976), dimethyl fumarate (2,767), and fingolimod (1,524) between January 1, 2011, and December 31, 2023, in persons with RRMS aged 18–55 years with at least ten years of lookback time (five years for dispensed drugs) and no evidence of previous IBD, matched with 61,065 general population comparator episodes selected from the Swedish population.
Setting: Sweden.
Exposure: Rituximab, comparator DMTs (natalizumab, dimethyl fumarate, fingolimod), or general population comparator.
Main Outcome: New-onset IBD, defined as ≥2 records on separate dates with the ICD-10 codes: K50 (Crohn's disease), K51 (ulcerative colitis), and/or K52.3 (indeterminate colitis).
Results: Among the 13,748 therapy episodes (mean age 35–38 years, female 69–75%) and 61,065 matched general population episodes, 164 IBD events occurred during follow-up: 40 with rituximab, 4 with comparator DMTs, and 120 in the general population. The crude incidence rate of IBD was 110 (95% CI 76–147) per 100,000 person-years for rituximab, 13 (3–30) for the comparator DMTs, and 41 (34–48) for the general population. After adjustment for demographics and MS characteristics, the hazard ratio for the comparator DMTs vs. rituximab was 0.10 (0.04–0.22). In the rituximab group, 62% of IBD events were classified as Crohn's disease, compared with 29% in the general population. The number needed to harm for rituximab vs. the comparator DMTs was 131 (93–228) at five years, after full adjustment. Conclusions and Relevance: Rituximab was associated with an increased risk of IBD compared with other modern MS therapies. Clinicians and persons with MS should consider IBD risk in treatment decisions and remain vigilant for gastrointestinal symptoms during anti-CD20 therapy.